

产品名称: **Latrepirdine**

产品别名: **Latrepirdine dihydrochloride; Dimebolin dihydrochloride**

生物活性:																		
Description	Latrepirdine dihydrochloride is a neuroactive compound with antagonist activity at histaminergic, α -adrenergic, and serotonergic receptors. Latrepirdine stimulates amyloid precursor protein (APP) catabolism and amyloid- β (A β) secretion.																	
IC₅₀ & Target	Amyloid- β (A β), Histaminergic receptor, α -adrenergic receptor, Serotonergic receptor[1]																	
In Vitro	Latrepirdine has been reported to possess several properties that are potentially relevant to the treatment of neurodegenerative diseases: (1) protection of cultured cells from the cytotoxicity of amyloid- β (A β) peptide; (2) stabilization of mitochondrial function and calcium homeostasis; (3) modulation of A β release from cultured cells, isolated intact nerve terminals, and from hippocampal neurons in living mouse brain; and (4) promotion of neurogenesis in the murine hippocampus. Treatment of cultured mammalian cells with Latrepirdine leads to enhanced mTOR- and Atg5-dependent autophagy. Latrepirdine modulates Atg5-dependent autophagic activity in a dose-dependent manner and via the mTOR-signaling pathway. HeLa cells stably expressing LC3 fused are treated with EGFP (eGFP-LC3) for 3 or 6 hours in the absence or presence of 50 μ M Latrepirdine. Treatment with Latrepirdine for 3 or 6 hours markedly enhances the number of eGFP-LC3 punctae, indicating that Latrepirdine induces formation of autophagosomes. Next, mouse N2a neuroblastoma cells are treated in the absence (vehicle) or presence of 5 nM, 500 nM or 50 μ M Latrepirdine for 3 or 6 hours in order to determine the effects of acute drug treatment on the regulation of autophagy. A significant and dose-dependent increase is observed in LC3-II levels in N2a cells following 3- or 6-hour treatment with either 500 nM or 50 μ M Latrepirdine. A significant decrease of p-mTOR and p-S6K from N2a cells treated with 50 μ M Latrepirdine for 3 hours is observed, whereas the total mTOR and p70S6K levels remain relatively constant[1].																	
In Vivo	Latrepirdine treatment of TgCRND8 transgenic mice is associated with improved learning behavior and with a reduction in accumulation of A β 42 and α -synuclein. Male, 90-day-old TgCRND8 mice or their wild-type littermates (nTg) receive 31 consecutive once daily i.p. injections of either 3.5 mg/kg Latrepirdine or 0.9% saline (vehicle). At the culmination of treatment, mice are tested for cued and contextual fear conditioning using a paradigm that has been widely accepted for evaluating learning and memory deficits in APP transgenic mice. A significant increase in cued memory only among Latrepirdine-versus vehicle-treated TgCRND8 mice (p=0.01) is observed. A weak, non-significant trend toward an improvement in contextual memory among Latrepirdine-versus vehicle-treated mice (p=0.099) is also observed[1].																	
	<p>In Vitro:</p> <p>DMSO : 6.4 mg/mL (16.31 mM; Need warming)</p> <table border="1"> <thead> <tr> <th rowspan="2">Preparing Stock Solutions</th> <th>Solvent Mass Concentration</th> <th>1 mg</th> <th>5 mg</th> <th>10 mg</th> </tr> </thead> <tbody> <tr> <td>1 mM</td> <td>2.5486 mL</td> <td>12.7431 mL</td> <td>25.4861 mL</td> </tr> <tr> <td>5 mM</td> <td>0.5097 mL</td> <td>2.5486 mL</td> <td>5.0972 mL</td> </tr> <tr> <td>10 mM</td> <td>0.2549 mL</td> <td>1.2743 mL</td> <td>2.5486 mL</td> </tr> </tbody> </table> <p>*请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液。一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。</p> <p>储备液的保存方式和期限 -80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。</p> <p>In Vivo:</p>	Preparing Stock Solutions	Solvent Mass Concentration	1 mg	5 mg	10 mg	1 mM	2.5486 mL	12.7431 mL	25.4861 mL	5 mM	0.5097 mL	2.5486 mL	5.0972 mL	10 mM	0.2549 mL	1.2743 mL	2.5486 mL
Preparing Stock Solutions	Solvent Mass Concentration		1 mg	5 mg	10 mg													
	1 mM	2.5486 mL	12.7431 mL	25.4861 mL														
5 mM	0.5097 mL	2.5486 mL	5.0972 mL															
10 mM	0.2549 mL	1.2743 mL	2.5486 mL															

<p>Solvent&Solubility</p>	<p>请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：</p> <p>——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶</p> <p>1.请依序添加每种溶剂： 10% DMSO→40% PEG300 →5% Tween-80 → 45% saline Solubility: ≥ 0.5 mg/mL (1.27 mM); Clear solution 此方案可获得 ≥ 0.5 mg/mL (1.27 mM, 饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 5.0 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀向上述体系中加入 50 μL Tween-80，混合均匀；然后继续加入 450 μL 生理盐水定容至 1 mL。</p> <p>2.请依序添加每种溶剂： 10% DMSO→ 90% (20% SBE-β-CD in saline) Solubility: ≥ 0.5 mg/mL (1.27 mM); Clear solution 此方案可获得 ≥ 0.5 mg/mL (1.27 mM, 饱和度未知) 的澄清溶液。 以 1 mL 工作液为例，取 100 μL 5.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。</p> <p>3.请依序添加每种溶剂： 10% DMSO →90% corn oil Solubility: ≥ 0.5 mg/mL (1.27 mM); Clear solution 此方案可获得 ≥ 0.5 mg/mL (1.27 mM, 饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。 以 1 mL 工作液为例，取 100 μL 5.0 mg/mL 的澄清 DMSO 储备液加到 900 μL 玉米油中，混合均匀。</p>
<p>References</p>	<p>[1]. Steele JW, et al. <u>Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model.</u> Mol Psychiatry. 2013 Aug;18(8):889-97.</p>
<p>实验参考：</p>	
<p>Cell Assay</p>	<p>N2a cells, stable human cervical carcinoma (HeLa) cells expressing EGFP-LC3, and mouse embryonic fibroblasts (MEFs) derived from wildtype mice or ATG5^{-/-} mice are maintained in "growth medium" (high glucose Dulbecco's modified Eagle's medium supplemented with 10% FBS and 100 units/mL Penicillin/Streptomycin) at 37°C, 5% CO₂. N2a cells stably transfected with APPK670N, M671L are maintained in growth medium supplemented with 0.2 mg/mL G418. Cells are washed 1× with ice cold PBS (pH 7.4) then incubated with either Latrepirdine (5 nM, 500 nM or 50 μM) or vehicle (growth medium). Following 3-, 6-, or 24-hour of treatment, cells are washed 1x with ice cold PBS, and collected in lysis buffer (50 mM Tris-HCl, 150 mM NaCl, 1 mM Pepstatin, 1 mM PMSF, 1% Triton X-100, EDTA-free mini-complete protease inhibitor cocktail tablet) then centrifuged (14,000 RPM) for 15 minutes at 4°C. For time-course experiments, cells are washed 2× with ice-cold PBS (pH 7.4) and incubated for the indicated time in serum-free DMEM containing 50 μg/mL CHX or 50 μg/mL Cycloheximide (CHX)+50 μg/mL Chloroquine (CQ). Baseline (T₀) samples are collected immediately prior to treatment[1]</p>
	<p>Mice[1] Male 53-55-day-old TgCRND8 mice (N=25) are randomly distributed into either of the two treatment groups: Latrepirdine (n=13 TgCRND8) or vehicle (n=12 TgCRND8). Animals receive 21 consecutive once daily intraperitoneal injections of either 3.5 mg/kg Latrepirdine or 0.9% saline (vehicle). 90-day-old male TgCRND8 mice (N=28) or their wild-type littermates (N=56) are randomly</p>

Animal Administration	distributed into either of two treatment groups: Latrepirdine (n=13 TgCRND8; n=21 nTg) or vehicle (n=15 TgCRND8; n=25 nTg). Following treatment, animals are sacrificed and transcardially perfused with ice-cold PBS (pH 7.4). Male 90-day-old (n=5 per genotype) or 120-day-old (n=6 per genotype) TgCRND8 mice or their non-transgenic littermates are sacrificed and transcardially perfused with ice-cold PBS (pH 7.4). One hemisphere from each mouse is post-fixed in 4% paraformaldehyde in PBS (pH 7.4) for histological analysis and the other hemisphere is dissected and snap-frozen for biochemical analysis.
References	[1]. Steele JW, et al. Latrepirdine improves cognition and arrests progression of neuropathology in an Alzheimer's mouse model. <i>Mol Psychiatry</i> . 2013 Aug;18(8):889-97.



源叶生物